The U.S. Food and Drug Administration (FDA) has approved the first generic form of the blood thinner Lovenox (enoxaparin sodium) for the treatment of deep vein thrombosis. Lovenox is made from the blood-thinning medication heparin. FDA officials report that about 100,000 cases of pulmonary embolism due to deep vein thrombosis are reported each year in the United States, making it the third-most common cause of death among people in hospitals.
Read moreI’ve grown a new appreciation for people who have to give themselves shots on a daily basis. Yes, I mean shots with needles. Many of... Read more »
Since I got pregnant, my body has done one somersault after another. I’m only four months along, but have experienced more nausea than... Read more »
Despite the rain here in West Virginia, Halloween brought out dozens of trick-or-treaters to my neighborhood. There were skeletons,... Read more »
The plan was simple and well thought out by my three doctors. My pregnancy was considered high-risk because of my history of stroke. So,... Read more »
The daily routine of putting two injections in my stomach is really getting old. Some days it goes very smoothly, but some days I psych... Read more »
Stroke patients who suffer from paralysis are helped more by Lovenox than heparin, a new study suggests. Researchers gave 1,762 stroke patients who... Read more »
The U.S. Food and Drug Administration (FDA) has given priority review status to Lovenox for the treatment of acute heart attack. The FDA grants... Read more »
The U.S. Food and Drug Administration has given expanded approval for the blood thinner Lovenox to treat the most severe form of heart attack. The... Read more »
Source: ADAM Encyclopedia
A parathyroid biopsy is the removal of a small piece of a parathyroid gland for examination under a microscope. The parathyroid glands are found just... Read more »
Source: eOrthopod
Any one who has had a total hip or total knee replacement knows that a major concern after surgery is the formation of blood clots. Blood clots can... Read more »